---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-022587"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:20:22.848753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics Q2 2022 net loss $8.5M, improved from $19.9M YoY

## Summary
- GAAP loss from continuing operations $8.2M in Q2 2022 vs $10.7M in Q2 2021.
- Adjusted net loss (non-GAAP) $7.3M in Q2 2022 vs $18.0M in prior year.
- Six-month adjusted net loss $1.8M vs $36.1M in H1 2021, driven by discontinued operations.
- CEO highlights BET inhibitor platform potential for immuno-inflammatory diseases.
- No revenue reported; company remains in development stage.

## SEC filing metadata
- accession: 0001628280-22-022587
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/0001628280-22-022587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/mnlo-20220812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-022587
- JSON: https://secwatch.observer/filing/0001628280-22-022587.json
- Plain text: https://secwatch.observer/filing/0001628280-22-022587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.